Filter Results

Clinical Studies

Closed for Enrollment

  • CNTO1959COR1001:A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis Jacksonville, Fla., Scottsdale/Phoenix, Ariz. This is a proof-of-concept study to evaluate the preliminary clinical activity of guselkumab in subjects with Familial Adenomatous Polyposis. The study is designed to determine if guselkumab has clinical activity in the colorectum and duodenum, by reducing the number of polyps over a period of 24 weeks.
  • Detection of Colorectal Cancer or Advanced Neoplasia by Stool DNA in Lynch Syndrome: CORAL Study (CORAL) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to to determine the sensitivity and specificity of a second-generation multi-target stool DNA test (mt-sDNA 2.0) (Cologuard 2.0®, Exact Sciences Corporation) for colorectal neoplasia (CRN) in subjects with Lynch syndrome.

     
  • Mayo Clinic Cancer Genomics Service Line Biorepository Rochester, Minn., Eau Claire, Wis., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The goal of the study is to create a database of clinical information and a repository of biological specimens for genetic, molecular and microbiological research to better understand hereditary cancer and help develop new therapies and preventive strategies.
  • Whole Exome Sequencing and Other Omics in Human Disease Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to test new technology called Next Generation Sequencing (NGS) that may help identify possible useful genetic information for your clinical care. NGS is a procedure that looks at all of your genes (the genetic material you have inherited from your parents). In this study, we want to collect detailed family history of enrolled patients, when available through an electronic-based, pedigree tool, identify exomic variants in patients using whole exome sequencing, understand how patients use the results of the genomic sequencing, and create a data repository of clinical phenotypes of patients linked to their genomic variant.

    We may conduct additional research on the information using various computational programs to better understand the genetic changes being reported. We also want to store samples and genetic information for future research using further tests to determine the clinical significance of genetic variants identified during the genomic testing process.
.